D.E. Shaw & Co’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.61M Buy
+56,589
New +$1.93M ﹤0.01% 3084
2025
Q3
Sell
-7,776
Closed -$255K 4549
2025
Q2
$255K Sell
7,776
-17,579
-69% -$571K ﹤0.01% 3960
2025
Q1
$818K Sell
25,355
-42,107
-62% -$1.56M ﹤0.01% 3213
2024
Q4
$2.06M Sell
67,462
-49,834
-42% -$1.6M ﹤0.01% 2710
2024
Q3
$3.29M Buy
117,296
+11,711
+11% +$289K ﹤0.01% 2307
2024
Q2
$2.4M Sell
105,585
-49,610
-32% -$1.14M ﹤0.01% 2492
2024
Q1
$4.72M Buy
155,195
+46,179
+42% +$1.55M ﹤0.01% 1929
2023
Q4
$3.89M Buy
109,016
+37,266
+52% +$1.39M ﹤0.01% 2111
2023
Q3
$3.14M Sell
71,750
-80,249
-53% -$3.91M ﹤0.01% 2220
2023
Q2
$7.5M Sell
151,999
-26,828
-15% -$1.24M 0.01% 1574
2023
Q1
$7.41M Buy
178,827
+62,764
+54% +$2.6M 0.01% 1614
2022
Q4
$5.15M Sell
116,063
-77,394
-40% -$3.23M 0.01% 2063
2022
Q3
$7.57M Sell
193,457
-20,533
-10% -$939K 0.01% 1622
2022
Q2
$8.74M Buy
213,990
+119,314
+126% +$5.65M 0.01% 1516
2022
Q1
$6.22M Buy
94,676
+52,251
+123% +$3.39M 0.01% 2069
2021
Q4
$2.95M Buy
42,425
+12,677
+43% +$921K ﹤0.01% 2976
2021
Q3
$2.07M Buy
29,748
+7,628
+34% +$587K ﹤0.01% 3006
2021
Q2
$1.75M Sell
22,120
-13,180
-37% -$958K ﹤0.01% 3078
2021
Q1
$2.31M Sell
35,300
-95,773
-73% -$5.9M ﹤0.01% 2466
2020
Q4
$7.3M Sell
131,073
-120,741
-48% -$5.22M 0.01% 1579
2020
Q3
$10M Sell
251,814
-126,540
-33% -$5.37M 0.01% 1245
2020
Q2
$17M Buy
378,354
+200,021
+112% +$8.71M 0.02% 869
2020
Q1
$5.99M Buy
178,333
+58,564
+49% +$2.11M 0.01% 1333
2019
Q4
$3.89M Buy
119,769
+18,294
+18% +$521K ﹤0.01% 1927
2019
Q3
$2.53M Sell
101,475
-88,278
-47% -$2.52M ﹤0.01% 2182
2019
Q2
$5.66M Sell
189,753
-110,456
-37% -$3.22M 0.01% 1508
2019
Q1
$8.04M Buy
300,209
+29,294
+11% +$890K 0.01% 1249
2018
Q4
$8.29M Buy
270,915
+96,176
+55% +$3M 0.01% 1213
2018
Q3
$6.12M Sell
174,739
-39,559
-18% -$1.25M 0.01% 1435
2018
Q2
$5.8M Buy
214,298
+21,225
+11% +$499K 0.01% 1424
2018
Q1
$3.96M Buy
193,073
+39,546
+26% +$714K 0.01% 1562
2017
Q4
$2.8M Buy
153,527
+41,844
+37% +$829K ﹤0.01% 1886
2017
Q3
$2.5M Buy
111,683
+27,743
+33% +$627K ﹤0.01% 1865
2017
Q2
$2.04M Buy
83,940
+54,308
+183% +$1.15M ﹤0.01% 1967
2017
Q1
$567K Sell
29,632
-103,363
-78% -$1.81M ﹤0.01% 2663
2016
Q4
$2.6M Buy
132,995
+44,462
+50% +$806K ﹤0.01% 1791
2016
Q3
$1.4M Buy
88,533
+22,558
+34% +$347K ﹤0.01% 2166
2016
Q2
$932K Buy
65,975
+1,314
+2% +$20K ﹤0.01% 2450
2016
Q1
$1.09M Buy
64,661
+33,664
+109% +$592K ﹤0.01% 2300
2015
Q4
$696K Sell
30,997
-25,211
-45% -$520K ﹤0.01% 2879
2015
Q3
$1.23M Buy
56,208
+47,866
+574% +$1.2M ﹤0.01% 2462
2015
Q2
$206K Sell
8,342
-4,305
-34% -$96.1K ﹤0.01% 3572
2015
Q1
$259K Sell
12,647
-43,334
-77% -$840K ﹤0.01% 3362
2014
Q4
$1.12M Buy
55,981
+15,992
+40% +$274K ﹤0.01% 2747
2014
Q3
$589K Sell
39,989
-9,382
-19% -$149K ﹤0.01% 3225
2014
Q2
$907K Sell
49,371
-26,068
-35% -$434K ﹤0.01% 3035
2014
Q1
$1.42M Buy
75,439
+38,969
+107% +$799K ﹤0.01% 2722
2013
Q4
$681K Sell
36,470
-239
-0.7% -$3.48K ﹤0.01% 3485
2013
Q3
$403K Buy
36,709
+11,747
+47% +$116K ﹤0.01% 3726
2013
Q2
$237K Buy
+24,962
New +$217K ﹤0.01% 3691

Other funds holding ATRC

D.E. Shaw & Co's ATRC Position: Q1 2026 in Review

D.E. Shaw & Co opened a new position in AtriCure (ATRC) in Q1 2026: 56,589 shares worth $1.61M. The stake represents ﹤0.01% of the portfolio and ranks #3084 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in ATRC as recently as Q2 2025.

D.E. Shaw & Co first reported a position in ATRC in Q2 2013 and has held it in 50 quarters since. The position peaked at $17M in Q2 2020. 223 funds tracked by Wall St. Rank hold ATRC as of Q1 2026.

  • D.E. Shaw & Co held 56,589 shares of AtriCure worth $1.61M as of Q1 2026.
  • AtriCure was a new D.E. Shaw & Co position in Q1 2026.
  • AtriCure made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3084 holding.
  • D.E. Shaw & Co first reported a position in AtriCure in Q2 2013 and has held it in 50 quarters since.
  • D.E. Shaw & Co's AtriCure position peaked at $17M in Q2 2020.
  • 223 funds tracked by Wall St. Rank held AtriCure as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.